Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is a common cause of acute kidney injury in the elderly. This patient group is particularly susceptible to disease-related morbidity and mortality, and to adverse effects of induction immunosuppression. A new study adds to the debate on the most appropriate way to treat this vulnerable group of patients.
Access options
Subscribe to Journal
Get full journal access for 1 year
$209.00
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
Moutzouris, D. A. et al. Renal biopsy in the very elderly. Clin. J. Am. Soc. Nephrol. 4, 1073–1082 (2009).
- 2
Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology (Oxford) 44, 495–501 (2005).
- 3
Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87, 203–209 (2008).
- 4
Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).
- 5
Flossman, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488–494 (2011).
- 6
Mukhtyar, C. & Luqmani, R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin. Exp. Rheumatol. 25 (Suppl. 47), 120–129 (2007).
- 7
Bomback, A. S. et al ANCA-associated glomerulonephritis in the very elderly. Kidney Int. doi:10.1038/ki.2010.489.
- 8
de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).
- 9
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
- 10
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
Author information
Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tarzi, R., Pusey, C. Risks and rewards of treating elderly patients with vasculitis. Nat Rev Nephrol 7, 253–255 (2011). https://doi.org/10.1038/nrneph.2011.30
Published:
Issue Date:
Further reading
-
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management
Drugs & Aging (2019)
-
Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis
Therapeutic Apheresis and Dialysis (2019)
-
Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study
Modern Rheumatology (2017)
-
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis
Clinical Journal of the American Society of Nephrology (2015)
-
Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy
Arthritis & Rheumatology (2015)
